X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs PIRAMAL ENTERPRISES - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES PIRAMAL ENTERPRISES DIVIS LABORATORIES/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 31.3 39.0 80.4% View Chart
P/BV x 5.4 3.2 167.5% View Chart
Dividend Yield % 0.9 0.8 121.5%  

Financials

 DIVIS LABORATORIES   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
PIRAMAL ENTERPRISES
Mar-17
DIVIS LABORATORIES/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,2222,095 58.3%   
Low Rs7841,025 76.5%   
Sales per share (Unadj.) Rs153.1492.8 31.1%  
Earnings per share (Unadj.) Rs39.972.6 55.1%  
Cash flow per share (Unadj.) Rs44.694.7 47.1%  
Dividends per share (Unadj.) Rs10.0021.00 47.6%  
Dividend yield (eoy) %1.01.3 74.1%  
Book value per share (Unadj.) Rs201.8862.5 23.4%  
Shares outstanding (eoy) m265.47172.56 153.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.63.2 207.0%   
Avg P/E ratio x25.121.5 116.8%  
P/CF ratio (eoy) x22.516.5 136.5%  
Price / Book Value ratio x5.01.8 274.8%  
Dividend payout %25.028.9 86.5%   
Avg Mkt Cap Rs m266,266269,194 98.9%   
No. of employees `0009.74.0 242.6%   
Total wages/salary Rs m4,68717,939 26.1%   
Avg. sales/employee Rs Th4,175.021,190.3 19.7%   
Avg. wages/employee Rs Th481.54,470.1 10.8%   
Avg. net profit/employee Rs Th1,089.33,120.0 34.9%   
INCOME DATA
Net Sales Rs m40,64385,037 47.8%  
Other income Rs m7492,338 32.0%   
Total revenues Rs m41,39287,374 47.4%   
Gross profit Rs m14,46034,991 41.3%  
Depreciation Rs m1,2333,817 32.3%   
Interest Rs m2320,310 0.1%   
Profit before tax Rs m13,95313,202 105.7%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m3,3492,281 146.8%   
Profit after tax Rs m10,60412,520 84.7%  
Gross profit margin %35.641.1 86.5%  
Effective tax rate %24.017.3 138.9%   
Net profit margin %26.114.7 177.2%  
BALANCE SHEET DATA
Current assets Rs m40,10587,590 45.8%   
Current liabilities Rs m6,595185,578 3.6%   
Net working cap to sales %82.5-115.2 -71.6%  
Current ratio x6.10.5 1,288.5%  
Inventory Days Days11931 381.9%  
Debtors Days Days8148 169.7%  
Net fixed assets Rs m19,995108,523 18.4%   
Share capital Rs m531345 153.8%   
"Free" reserves Rs m53,043148,481 35.7%   
Net worth Rs m53,574148,826 36.0%   
Long term debt Rs m0144,957 0.0%   
Total assets Rs m61,585482,394 12.8%  
Interest coverage x618.41.7 37,478.4%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x0.70.2 374.4%   
Return on assets %17.36.8 253.5%  
Return on equity %19.88.4 235.3%  
Return on capital %26.112.0 218.3%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,38415,001 235.9%   
Fx outflow Rs m10,3995,150 201.9%   
Net fx Rs m24,9859,851 253.6%   
CASH FLOW
From Operations Rs m11,493-100,393 -11.4%  
From Investments Rs m-11,372-24,202 47.0%  
From Financial Activity Rs m-93135,705 -0.1%  
Net Cashflow Rs m2811,110 0.3%  

Share Holding

Indian Promoters % 52.0 52.9 98.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 4.0 295.0%  
FIIs % 19.0 26.6 71.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 16.5 104.2%  
Shareholders   31,796 93,274 34.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   FRESENIUS KABI ONCO.  ELDER PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 19, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - SANOFI INDIA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS